3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
35
Lymphoma
18
Urinary Bladder Neoplasms
10
Neoplasms
3
Melanoma
3
Leukemia
2
HIV Infections
2
Glioma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urothelial Carcinoma of the Bladder
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Survival Without Progression
1
Skin Neoplasms
1
Sarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Pathologic Complete Response
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Mesothelioma, Malignant
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Kidney Neoplasms
1
Desmoid Tumors
1
Interventions
Cyclophosphamide
33
fludarabine phosphate
19
Peripheral Blood Stem Cell Transplantation
19
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
15
Rituximab
14
Tacrolimus
13
Busulfan
12
Vincristine
11
Prednisone
11
Methotrexate
11
Filgrastim
11
Doxorubicin
11
Cyclosporine
11
Radiotherapy
10
Brentuximab Vedotin
10
Antilymphocyte Serum
10
Methylprednisolone
8
Cytarabine
8
Melphalan
7
Cisplatin
6
Ifosfamide
5
Gemcitabine
5
merphos
4
ibritumomab tiuxetan
4
Sirolimus
4
Flow Cytometry
4
Dexamethasone
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Large-Cell, Anaplastic
×
Vinblastine
×
Clear all
NCT07013565
2026-05-20
ACCELERATE
New York Medical College
Phase 2
Recruiting
20 enrolled